Abstract:Background: Pleural effusion is commonly observed in patients with advanced lung cancer and its molecular profiling has not been fully investigated. Cell-free (cf) DNA or RNA isolated from cancer patient’s plasma has allowed noninvasive tumor genome analysis, however, there are few study of detection and characterization of cfDNA or cfRNA in pleural effusions and its application in cancer patient treatment. Here we reported the utilization of cell free total nucleic acid (cfTNA) isolated from pleural fluid of late stage lung cancer patient with Next-generation sequencing (NGS) liquid biopsy assay-Oncomine™ Lung cfTNA Assay. The assay simultaneously query about 168 hotspots across ALK, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, and TP53, CNV (MET), gene fusions (ALK, RET, ROS1) as well as MET exon 14 skipping which have been frequently identified in NSCLC. A comprehensive study of these mutations provides information for therapy decision, disease monitor as well as new drug development. Methods: Ten paired cfTNA were isolated from plural fluid of Non-Small Cell Lung Cancer (NSCLC) subjects, and their matched tumor TNA were extracted from formalin-fixed paraffin-embedded (FFPE) cell pellet collected from same plural fluid. Libraries were prepared using Oncomine Lung Cell-Free Total Nucleic Acid Research Assay and sequenced with Ion S5 Sequencing instrument. Data were analyzed using Ion Reporter 5.6. Results: All cfTNA have been isolated from twenty patient pleural fluid (yield range is 41-1227 ng from 4ml fluid). Bioanalyzer profile of these cfTNA verified the fragmentation pattern, which is similar to cfTNA isolated from plasma. 20ng of cfTNA were tested with Oncomine™ cfDNA Lung assay test, matched somatic variants were detected at a frequency between 6.4% to 54.3% in cfDNA and between 1.2% to 67.6% in corresponding DNA isolated from FFPE. Conclusions: Oncomine™ Lung cfTNA research assay provided an easy, quick and reliable solution in detecting molecular profile using cfTNA isolated from pleural fluid. Molecular analysis of pleural fluid can be used in clinical practice for treatment of late stage cancer patients with pleural fluid. Legal entity responsible for the study: Shanghai Chest Hospital. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

AuNPs/DNAzyme/siRNA Three-Dimensional Nanomotor for CEACAM6 RNA Detection in Cerebrospinal Fluid and Gene Therapy of NSCLC

Application of Next Generation Sequencing in Pleural Effusion Molecular Profiling Using Oncomine™ Lung Cell-Free Total Nucleic Acid Research Assay.

Cerebrospinal fluid circulating tumor DNA for the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.

Biodegradable Nanosyringes for Intracellular Amplification-Based Dual-Diagnosis and Gene Therapy in Single Living Cells

Nanoparticles targeting at methylases with high correlation to N6-methyladenosine-related lncRNA signatures as potential therapy of kidney clear cell carcinoma

Unique Genomic Alterations of Cerebrospinal Fluid Cell-Free DNA Are Critical for Targeted Therapy of Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Application of Cerebrospinal Fluid Circulating Cell-Free DNA in the Diagnosis and Treatment of Leptomeningeal Metastases from Non-Small-cell Lung Cancer

Biomimetic Red Blood Cell Membrane-Mediated Nanodrugs Loading Ursolic Acid for Targeting NSCLC Therapy

NIR-IIb Fluorescence-Image Guided Synergistic Surgery/ Starvation/chemodynamic Therapy: an Innovative Treatment Paradigm for Malignant Non-Small Cell Lung Cancers

EGFR-specific Single-Chain Variable Fragment Antibody-Conjugated Fe3O4/Au Nanoparticles As an Active MRI Contrast Agent for NSCLC

Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug

Anti-EGFR ScFv Functionalized Exosomes Delivering LPCAT1 Specific Sirnas for Inhibition of Lung Cancer Brain Metastases

A Novel Signal-On Electrochemiluminescence Immunosensor for the Detection of NSCLC Antigen Biomarker Based on New Co-Reaction Accelerators

CXCR-4 Targeted, Short Wave Infrared (SWIR) Emitting Nanoprobes for Enhanced Deep Tissue Imaging and Micrometastatic Cancer Lesion Detection

Nanoplex Delivery of Sirna and Prodrug Enzyme for Multimodality Image-Guided Molecular Pathway Targeted Cancer Therapy.

A novel electrochemical biosensor for sensitive detection of non-small cell lung cancer ctDNA using NG-PEI-COFTAPB-TFPB as sensing platform and Fe-MOF for signal enhancement

Clinical diagnosis of EML4–ALK mutation in NSCLC by a gold nanoparticle beacon

Individual Au-Nanocube Based Plasmonic Nanoprobe for Cancer Relevant MicroRNA Biomarker Detection.

WITHDRAWN: Unique genomic alterations of cerebrospinal fluid cell-free DNA are critical for targeted therapy of non-small cell lung cancer with leptomeningeal metastasis

An advanced 3D DNA nanoplatform for spatiotemporally confined enhanced dual-mode biosensing MicroRNA in cancer cell

Novel nanoparticle AuNCs conjugated with Desmoglein-3 antibody for FL/CT dual-mode targeted imaging and precise treatment of lung squamous cell carcinoma